Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
LKQ$17.22-0.20(-1.14%)LKQ Corporation (LKQ) Faces Investor Scrutiny Amid Enterprise Resource Planning System Surprises, CEO Departure; Shares Trade Sharply Lower Again – HBSS[6:31:21 PM ET]ELE$16.00+0.12(+0.76%)Elemental Royalty Announces First Close of Royalty and Streaming Portfolio Alongside Upsized US$250M Credit Facility[6:30:00 PM ET]TTGXF$0.120.00(0.00%)Trans Canada Gold Closes Final Tranche of Non-Brokered Private Placement for Gross Proceeds of CDN $2,205,737 and Prepares for Phase 2 Drilling[6:30:00 PM ET]BLK$1,127.66+9.41(+0.84%)BlackRock® Canada Announces Final October Cash Distributions for the iShares® Premium Money Market ETF[6:30:00 PM ET]FSBC$44.50+0.41(+0.93%)Five Star Bancorp Announces Third Quarter 2026 Results[6:30:00 PM ET]HLLY$2.56+0.07(+2.81%)Holley Performance Brands and Amotiv Form Strategic Collaboration to Expand Brand Reach Across North America, Australia and New Zealand[6:30:00 PM ET]ELVR$24.90+1.37(+5.82%)Elevra Lithium Quarterly Activities Report[6:20:52 PM ET]KCLI$35.360.00(0.00%)Kansas City Life Declares Quarterly Dividend The Board of Directors of Kansas City Life Insurance Company declared a quarterly dividend of $0.18 per share on Oct. 26, 2026. The dividend will be...[6:09:00 PM ET]DSY$3.21-0.14(-4.18%)Big Tree Cloud Holdings Limited Announces Filing of Annual Report on Form 20-F for Fiscal Year 2026 Big Tree Cloud Holdings Limited ("Big Tree Cloud" or the "Company") (NASDAQ: DSY; DSYWW), a capital platform focusing on industrial integration and...[6:00:00 PM ET]GGB$4.65-0.45(-8.82%)Gerdau S.A. - Consolidated Information[6:00:00 PM ET]ULS$72.96-0.48(-0.65%)UL Solutions Opens Expanded Product Testing Facility in Vietnam[6:00:00 PM ET]POAS$1.50-0.43(-22.28%)Phaos Technology Holdings (Cayman) Limited Provides Required Going Concern Disclosure[6:00:00 PM ET]

ASND · NASDAQ

Ascendis Pharma A/S

$245.06 +1.69 (+0.69%)

Company overview

Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan, TransCon hGH for adults with GHD, TransCon parathyroid hormone for adult hypoparathyroidism, and TransCon CNP for pediatric achondroplasia. Additionally, the company develops TransCon Toll-like receptor 7/8 agonist for intratumoral delivery and TransCon IL-2 β/γ for systemic delivery. Founded in 2006, the company is headquartered in Hellerup, Denmark.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$15.3B
Employees
1,017
Headquarters
Hellerup
Website
ascendispharma.com
CEO
Jan Moller Mikkelsen
Listed
January 28, 2015
P/E
29.92
Dividend yield
0.00%

Company financials

Revenue
$868M
Gross profit
$765M
Operating income
-$6.9M
EBITDA
-$6.9M
Net income
$507M
EPS
$8.19
Total assets
$2B
Total debt
$898M
Gross margin
88.17%
Net margin
58.40%
Earnings yield
3.34%

Revenue segmentation

By product (FY 2025)

No product segmentation.

By region (FY 2025)

Showing FY 2025

Price chart

200.67221.82242.98264.13285.28
ASND 1D NASDAQ O242.00H244.58L240.79C243.37+0.38 (+0.16%)Vol575.67K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ASNDAscendis Pharma A/S Press release TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years GlobeNewswire
ASNDAscendis Pharma A/S Stock news Top Growth Stocks To Follow Now – October 16th Defense World
ASNDAscendis Pharma A/S Press release TransCon® CNP (navepegritide), administré une fois par semaine, reçoit un avis favorable du CHMP dans le traitement de l’achondroplasie chez l’enfant GlobeNewswire
ASNDAscendis Pharma A/S Press release Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children GlobeNewswire
ASNDAscendis Pharma A/S Stock news FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing Zacks Investment Research
ASNDAscendis Pharma A/S Press release Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026 GlobeNewsWire
ASNDAscendis Pharma A/S Stock news Ascendis Pharma: Back To Full Independence Seeking Alpha
ASNDAscendis Pharma A/S Stock news Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
ASNDAscendis Pharma A/S Stock news Why Is Ascendis Pharma Stock Trading Lower on Tuesday? Benzinga
ASNDAscendis Pharma A/S Stock news This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Benzinga
ASNDAscendis Pharma A/S Press release Ascendis Announces Planned $400 Million Share Repurchase Program GlobeNewsWire
ASNDAscendis Pharma A/S Press release Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases GlobeNewsWire
ASNDAscendis Pharma A/S Stock news Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX) Defense World
ASNDAscendis Pharma A/S Press release First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 GlobeNewswire
ASNDAscendis Pharma A/S Press release Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference GlobeNewsWire
ASNDAscendis Pharma A/S Press release Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 GlobeNewswire
ASNDAscendis Pharma A/S Stock news Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday Benzinga
ASNDAscendis Pharma A/S Stock news Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes Benzinga
ASNDAscendis Pharma A/S Press release Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) GlobeNewsWire
ASNDAscendis Pharma A/S Stock news This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Benzinga
See more
FAQ

Questions about Ascendis Pharma A/S

What does Ascendis Pharma A/S do?
Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan, TransCon hGH for adults with GHD, TransCon parathyroid hormone for adult hypoparathyroidism, and TransCon CNP for pediatric achondroplasia. Additionally, the company develops TransCon Toll-like receptor 7/8 agonist for intratumoral delivery and TransCon IL-2 β/γ for systemic delivery. Founded in 2006, the company is headquartered in Hellerup, Denmark.
What is ASND's market cap?
Ascendis Pharma A/S (ASND) is a listed stock with a live quote. The latest market cap on this page is $15.3B.
Where is Ascendis Pharma A/S headquartered?
Ascendis Pharma A/S is headquartered in Hellerup.
How do I get ASND news from the API?
Call GET /v1/news?tickers=ASND. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ASND news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ASND, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ASND price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs